Abstract

WILLS-SANIN, Beatriz; RINCON, Alejandra; MONTENEGRO, Ana Cristina  and  BUITRAGO-SANDOVAL, Andrés F.. Proprotein convertase subtilisin/kexin type 9 inhibitors: an alternative for treating dyslipidemias. Rev. Colomb. Cardiol. [online]. 2017, vol.24, n.4, pp.411-416.  Epub Feb 16, 2017. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2016.11.002.

International clinical practice guidelines recommend statins as the treatment of choice for managing dyslipidemias. However, despite evidence regarding the importance of controlling this condition, there is a significant percentage of adults who do not meet their target lipids with statins. This has stimulated the development of monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9. These drugs have been approved as adjuvants for the diet and the maximum tolerated statin dosage in familial hypercholesterolemia or clinical atherosclerosis in patients requiring an additional reduction of low-density lipoproteins. This article reviews current evidence regarding antibodies against proprotein convertase subtilisin/kexin type 9 with the goal of optimising clinical treatment of our patients.

Keywords : Hypercholesterolemia; Pharmacology; LDL cholesterol; Antibodies.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )